Development of Colon Targeted Hydrogel Tablet of Methotrexate 12+

📗 Colorectal cancer is second leading cause of deaths in the United States. Various approaches available for The poor site specificity of pH dependent systems, because of large variation in the pH of gastrointestinal tract, was well established. The timed-release systems release their load after a predetermined period of administration. These are designed to resist the release of the drug in stomach and small intestine and release of the drug takes place in colon. Methotrexate (MTX) is a used in the treatment of colon cancer and now a days rheumatic disease. MTX is a folate antimetabolite. MTX has since been used in the treatment of various malignancies including osteosarcoma, non-Hodgkin's lymphoma, Hodgkin's disease, cutaneous T cell lymphoma, lung cancer, colon cancer and breast cancer. The conventional dosage forms which are used for colorectal cancer normally dissolve and absorbs in the stomach and small intestine; thus a very less quantity of dose of drug reaches to colonic region. Aim of present work is to develop and characterize colon targeted tablet of MTX for for treatment of colorectal cancer using different polymer and excipient by compression coating technology.